Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity

Table 1

Baseline demographic and clinical characteristics of patients with rheumatoid arthritis who received anti-TNF-alpha-adalimumab therapy.

Characteristic	Number	%	Mean ± SD
Age (yrs)			54.51 ± 13.16
Body mass index (kg/m^2)			23.32 ± 3.50
DAS28 score			6.52 ± 0.72
Sex
Male	15	21
Female	56	79
Smoking
No	67	95
Yes	4	5.2
Alcohol consumption
No	68	96
Yes	3	4.2
Use of other RA mediations
Methotrexate
No	0	0
Yes	71	100
Hydroxychloroquine
No	0	0
Yes	71	100
Leflunomide
No	57	80
Yes	14	20
Cyclosporin
No	64	90
Yes	7	9.9
Sulfasalazine
No	59	84
Yes	12	17
Azathioprine
No	59	83
Yes	12	17

RA: rheumatoid arthritis; DAS28: disease activity score in 28 joints.